Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 3 studies | 30% ± 10% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 22% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 861.31 | 89 / 89 | 100% | 31.60 | 901 / 901 |
liver | 100% | 747.87 | 226 / 226 | 100% | 16.16 | 406 / 406 |
ovary | 100% | 766.41 | 180 / 180 | 100% | 18.14 | 430 / 430 |
thymus | 100% | 757.89 | 653 / 653 | 100% | 18.01 | 605 / 605 |
uterus | 100% | 926.61 | 170 / 170 | 100% | 22.31 | 459 / 459 |
prostate | 100% | 842.02 | 245 / 245 | 100% | 15.84 | 501 / 502 |
skin | 100% | 768.06 | 1807 / 1809 | 100% | 35.72 | 471 / 472 |
breast | 100% | 822.57 | 459 / 459 | 100% | 19.45 | 1114 / 1118 |
esophagus | 100% | 723.53 | 1439 / 1445 | 100% | 12.63 | 183 / 183 |
adrenal gland | 100% | 1104.79 | 258 / 258 | 100% | 18.94 | 229 / 230 |
brain | 99% | 598.01 | 2628 / 2642 | 100% | 29.73 | 705 / 705 |
bladder | 100% | 837.00 | 21 / 21 | 99% | 17.24 | 501 / 504 |
stomach | 100% | 634.01 | 358 / 359 | 100% | 12.98 | 285 / 286 |
intestine | 100% | 777.46 | 963 / 966 | 99% | 14.16 | 523 / 527 |
pancreas | 99% | 394.20 | 324 / 328 | 99% | 14.09 | 177 / 178 |
lung | 95% | 566.75 | 549 / 578 | 100% | 17.40 | 1155 / 1155 |
eye | 0% | 0 | 0 / 0 | 100% | 19.56 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 28.82 | 29 / 29 |
muscle | 100% | 1453.40 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 1187.74 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 16.52 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 10.12 | 1 / 1 |
adipose | 100% | 778.46 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 636.80 | 1332 / 1335 | 0% | 0 | 0 / 0 |
heart | 100% | 829.20 | 857 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 78% | 474.33 | 728 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_2001240 | Biological process | negative regulation of extrinsic apoptotic signaling pathway in absence of ligand |
GO_0051301 | Biological process | cell division |
GO_0005654 | Cellular component | nucleoplasm |
GO_0031965 | Cellular component | nuclear membrane |
GO_0005634 | Cellular component | nucleus |
GO_0019901 | Molecular function | protein kinase binding |
GO_0005515 | Molecular function | protein binding |
GO_0008270 | Molecular function | zinc ion binding |
Gene name | ZC3HC1 |
Protein name | Zinc finger C3HC-type protein 1 (Nuclear-interacting partner of ALK) (hNIPA) (Nuclear-interacting partner of anaplastic lymphoma kinase) Zinc finger C3HC-type containing 1 ZC3HC1 protein |
Synonyms | HSPC216 NIPA |
Description | FUNCTION: Essential component of a SCF-type E3 ligase complex, SCF(NIPA), a complex that controls mitotic entry by mediating ubiquitination and subsequent degradation of cyclin B1 (CCNB1). Its cell-cycle-dependent phosphorylation regulates the assembly of the SCF(NIPA) complex, restricting CCNB1 ubiquitination activity to interphase. Its inactivation results in nuclear accumulation of CCNB1 in interphase and premature mitotic entry. May have an antiapoptotic role in NPM-ALK-mediated signaling events. . |
Accessions | ENST00000467642.5 Q86WB0 ENST00000484432.1 F8WF13 ENST00000358303.9 [Q86WB0-1] ENST00000648450.1 ENST00000360708.9 [Q86WB0-3] F8WAU5 F8WBD7 ENST00000483827.1 C9J0I9 ENST00000481503.5 ENST00000311873.9 [Q86WB0-2] ENST00000470651.1 F8WDK5 Q9BWJ8 |